Full Press Release Details
ANNOUNCES RESULTS OF ANNUAL MEETING OF STOCKHOLDERS HELD TODAY
N.Y., August 17, 2021 - NanoVibronix, Inc., (NASDAQ: NAOV) (the "Company"), a healthcare device company that
produces the UroShield and PainShield Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, announced that the
Company's Annual Meeting of Stockholders was held today virtually and broadcast live at www.virtualshareholdermeeting.com/NAOV2021.
of the resolutions submitted for stockholder approval were adopted, including:
| Election of the six director nominees | ||
| Approval of the amendment to the company's amended and restated certificate of incorporation to increase the number of authorized shares of common stock. | ||
| Ratification of appointment of Marcum LLP as the company's independent registered public accounting firm | ||
| Approval, on an advisory basis, of the compensation paid to the company's named executive officers | ||
| Approval, on an advisory basis, of the frequency of future advisory votes on the compensation paid to the company's named executive officers |
Inc. (NASDAQ: NAOV) is a medical device company headquartered in Elmsford, New York, with research and development in Nesher, Israel,
focused on developing medical devices utilizing its patented low intensity surface acoustic wave (SAW) technology. The proprietary technology
allows for the creation of low-frequency ultrasound waves that can be utilized for a variety of medical applications, including for disruption
of biofilms and bacterial colonization, as well as for pain relief. The devices can be administered at home without the assistance of
medical professionals. The Company's primary products include PainShield and UroShield , which are portable devices suitable
for administration at home without assistance of medical professionals. Additional information about NanoVibronix is available at: www.nanovibronix.com.
press release contains "forward-looking statements." Such statements may be preceded by the words "intends,"
"may," "will," "plans," "expects," "anticipates," "projects,"
"predicts," "estimates," "aims," "believes," "hopes," "potential"
or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject
to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or
quantified; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such
risks and uncertainties include, without limitation, risks and uncertainties associated with: (i) our history of losses and expectation
of continued losses, (ii) the geographic, social and economic impact of COVID-19 on the Company's business operations, (iii) our
ability to raise funding for, and the timing of, clinical studies and eventual U.S. Food and Drug Administration approval of our product
candidates, (iv) regulatory actions that could adversely affect the price of or demand for our approved products, (v) market acceptance
of existing and new products, (vi) favorable or unfavorable decisions about our products from government regulators, insurance companies
or other third-party payers, (vii) risks of product liability claims and the availability of insurance, (viii) our ability to successfully
develop and commercialize our products, (ix) our ability to generate internal growth, (x) risks related to computer system failures and
cyber-attacks, (xi) our ability to obtain regulatory approval in foreign jurisdictions, (xii) uncertainty regarding the success of our
clinical trials for our products in development, (xiii) risks related to our operations in Israel, including political, economic and
military instability, (xiv) the price of our securities is volatile with limited trading volume, (xv) our ability to comply with the
continued listing requirements of the NASDAQ capital market, (xvi) our ability to maintain effective internal control over financial
reporting and to remedy identified material weaknesses, (xvii) we are a "smaller reporting company" and have reduced disclosure
obligations that may make our stock less attractive to investors, (xviii) our intellectual property portfolio and our ability to protect
our intellectual property rights, (xix) our ability to recruit and retain qualified regulatory and research and development personnel,
(xx) unforeseen changes in healthcare reimbursement for any of our approved products, (xxi) the adoption of health policy changes and
health care reform, (xxii) lack of financial resources to adequately support our operations, (xxiii) difficulties in maintaining commercial
scale manufacturing capacity and capability, (xxiv) our ability to generate internal growth, (xxv) changes in our relationship with key
collaborators, (xxvi) changes in the market valuation or earnings of our competitors or companies viewed as similar to us, (xxvii) our
failure to comply with regulatory guidelines, (xxviii) uncertainty in industry demand and patient wellness behavior, (xxix) general economic
conditions and market conditions in the medical device industry, (xxx) risks related to our operations in Israel, (xxxi) future sales
of large blocks of our common stock, which may adversely impact our stock price, and (xxxii) depth of the trading market in our common
stock. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements
is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report
on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge
on the SEC's web site at: http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking
statements as a result of new information, future events, or otherwise, except as required by law.
Maas, Managing Principal, Hayden IR, LLC